Lavior Pharma Announces The Addition Of Rear Admiral (Ret.) Louis Tripoli, MD To The Scientific Advisory Board

Lavior Pharma Inc., an International advanced diabetic wound and skincare Company headquartered in Miami, Florida, announced the appointment of Rear Admiral (RDML) Louis Tripoli, MD, USN, (ret.), to the Company’s Scientific Advisory Board. Admiral Tripoli served in many roles in the US Navy and was most recently the Command Surgeon for the US Indo-Pacific Command. His other assignments were as Group Surgeon for the Fourth Civil Affairs Group (US Marine Corps) in Iraq, Officer in Charge of the Navy Expeditionary Medical Unit in Landstuhl, Germany, Senior Medical Officer at Navy Personnel Command, Commanding Officer of Expeditionary Medical Facility Camp Pendleton, and others. Admiral Tripoli’s military awards and achievements include the Defense Superior Service Medal, several Legion of Merit and Meritorious Services Medals, the Bronze Star for serving in combat with the US Marines, the Fleet Marine Force ribbon, and many others.

Dr. Tripoli graduated with distinction from Harvard University and the University of Pittsburgh School of Medicine and received board certification in Internal Medicine and is considered an expert in infectious diseases. He has held faculty appointments at the University of Pittsburgh, Johns Hopkins University, the St. Louis University Institute for Biosecurity, and the Uniformed Services University of the Health Sciences, where he is currently an Adjunct Associate Professor of Medicine. Dr. Tripoli is a member of numerous medical societies, including the Infectious Diseases Society of America (IDSA), American College of Physicians (ACP), American Medical Association (AMA), the American Academy of Family Physicians (AAFP), the Association of Military Surgeons of the United States (AMSUS), and the Military Officers Association of America (MOAA). He is the author of many scientific research articles and several book chapters, including a portion of the Pandemic and Emerging Infectious Disease Operation Plan, which was used in 2020 for the Coronavirus outbreak. He also holds two U.S. patents for medication safety technology.

From his distinguished naval service to his leadership in multiple global health initiatives, we are excited to welcome Dr. Tripoli to the Scientific Advisory Board. Dr. Tripoli brings more than 30 years of military and private sector medical experience and will provide guidance on our scientific and health strategy as we continue to rapidly expand our research and development efforts in diabetes and other fields,” states Gilad Savion, Founder and CEO of LAVIOR. 

Dr. Tripoli shares, “I look forward to joining Lavior’s Scientific Advisory Board and assisting them in their strategy to share their extensive research, scientific advancements, and patient outcomes. They have made tremendous progress and continue to show success in their innovative approach to healing diabetic wounds. Their continuing advances in diabetic wound care will certainly avert complications and alleviate suffering for many patients.”

About Lavior Pharma Inc.

LAVIOR is the only company exclusively dedicated to the therapeutic diabetes skin care market.  The LAVIOR skincare product line soothes and heals some of the most widespread and challenging skin problems – diabetic ulcers, wounds, burns, eczema/atopic dermatitis, bacterial and fungal infections, skin irritations, and cracked skin. LAVIOR’s line of products is based on the proven efficacy of the Inula AGS RIED botanical species. They are developed using the highest quality, pharmaceutical grade ingredients; manufactured and tested to deliver safe, effective, and compliant products. Backed by over 13 years of extensive research and clinical trials, proven clinical safety and efficacy, they consistently outperform conventional treatments.

For more information on Lavior Pharma and its products, please visit www.lavior.com

For Media or other Inquiries, please contact: 

Anabelle Savion 
Chief Marketing Officer
Phone: (+1) 9178373355